Genetické a epigenetické základy radiorezistence nádorových buněk prostaty

Stiahnuť PDF English version

Autori: Denis Kutilin
Pôsobisko autorov: National Medical Research Oncology Center, Rostov-on-Don, Russian Federation
Vyšlo v časopise: Klin Onkol 2021; 34(3): 220-234
Kategória: Původní článek
doi: https://doi.org/10.48095/ccko2021220

Súhrn

Východiska: Radiační terapie hraje hlavní roli v léčbě karcinomu prostaty, ale výskyt radiorezistentních forem tohoto onemocnění diktuje potřebu personalizovaného přístupu založeného na údajích z genetických a epigenetických markerů. Takové markery zahrnují změnu počtu kopií, expresi genů a mikroRNA. Cíl: Cílem studie bylo ověřit seznam potenciálních prediktorů radiorezistence nádorových buněk prostaty v modelovém experimentu založeném na stanovení variací počtu genových kopií, genové transkripční aktivity a exprese mikroRNA. Materiál a metody: Ve studii byla použita buněčná kultura karcinomu prostaty PC-3. Stanovení relativního počtu kopií a exprese 32 genů (BRCA1, BRCA2, PTEN, CASP3, CASP8, BAX, BCL2, CASP9, P53, MDM2, AKT1, ATM, BRIP1, CDK1, CDKN1B, CCND1, CCND3, FGFRAD250, RUAP80, Rif1, RNF168, TopBP1, HIST, H2AX, EXO1, XRCC4, RBBP8, EP300, LIG4, C-FLIP) a 15 mikroRNA (let-7, miR-7, miR15a/16, miR-17-92, miR-18a, miR-21, miR-24, miR-26b, miR-34s, miR-99a, miR-100, miR-101, miR-106, miR-663) bylo provedeno pomocí metody kvantitativní polymerázové řetězové reakce v reálném čase. Bylo zjištěno, že denní ozáření buněk PC-3 na lineárním urychlovači Novalis TX při dávkách 6 a 7 Gy po dobu 5 dnů vede k významnému snížení celkového počtu buněk a počtu životaschopných buněk. Nicméně po 5 dnech ozáření si asi 15 % původního počtu nádorových buněk prostaty zachovalo svou životaschopnost, což je způsobeno jejich zvláštními genetickými a epigenetickými vlastnostmi: zvýšený počet kopií a exprese BRCA2, CDK1, CDKN1B, H2AX, RAD50, XRCC4, RBBP8 a EP300 a snížený počet kopií a exprese genů CCND3, TP53 a BCL2, jakož i diferenciální exprese šesti mikroRNA (hsa-miR-18a-5p, hsa-miR-24-1-5p, hsa-miR- 99a-5p, hsa-miR-100-5p, hsa-miR-145-5p3, hsa-let-7a-2-3p). Závěr: Tato studie umožnila identifikovat genetické a epigenetické markery rezistence nádorových buněk prostaty na radiační terapii.

Klíčová slova:

radioterapie – karcinom prostaty – buněčná kultura – počet kopií genů – transkripční aktivita genů – mikro-RNA – apoptóza – oprava DNA

Zdroje

Zinkovich MS, Maksimov AY, Rozenko LY et al. Radioresistance as a factor of evolution of radiation therapy for prostate cancer. [online]. Available from: http://science-education.ru/ru/article/view?id=28627.
Chaiswing L, Weiss HL, Jayswal RD. Profiles of radioresistance mechanisms in prostate cancer. Crit Rev Oncog 2018; 23(1–2): 39–67. doi: 10.1615/CritRevOncog.2018025946.
Mottet N, Bellmunt J, Bolla M. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71(4): 618–629. doi: 10.1016/j.eururo.2016.08.003.
Negre-Salvayre A, Coatrieux C, Ingueneau C et al. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008; 153(1): 6–20. doi: 10.1038/sj.bjp.0707395.
Li Z, Pearlman AH, Hsieh P. DNA mismatch repair and the DNA damage response. DNA Repair (Amst) 2016; 38: 94–101. doi: 10.1016/j.dnarep.2015.11.019.
Sonveaux P. ROS and radiotherapy: More we care. Oncotarget 2017; 8(22): 35482–35483. doi: 10.18632/oncotarget.16613.
Kutilin DS, Airapetova TG, Anistratov PA et al. Copy number variation in tumor cells and extracellular dna in patients with lung adenocarcinoma. Bull Exp Biol Med 2019; 167(6): 771–778. doi: 10.1007/s10517-019-04620-y.
Kutilin DS, Zinkovich MS, Gusareva MA et al. Gene copy number variation as a factor of radiation resistance of prostate tumor cells. Modern problems of science and education 2020. [online]. Available from: http://science-education.ru/ru/article/view?id=29866.
ATCC, Standards Development Organization is accredited by the American National Standards Institute (ANSI). [online]. Available from: http://www.lgcstandards-atcc.org.
Kutilin DS, Sagakyants AB, Zinkovich MS et al. Effects of various radiotherapy doses on survival of prostate tumor cells line PC-3. [online]. Available from: http://www.science-education.ru/article/view?id=28740.
Kit OI, Vodolazhsky DI, Kutilin DS et al. Changes in the number of copies of genetic loci in gastric cancer. Mol Biol (Mosk) 2015; 49(4): 658–666. doi: 10.7868/S0026898415040096.
Kutilin DS. Regulation of gene expression of cancer/testis antigens in colorectal cancer patients. Mol Biol (Mosk) 2020; 54(4): 580–595. doi: 10.31857/S0026898420040096.
Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. [online]. Available from: https://rdcu.be/b6uOX. doi: 10.1186/gb-2002-3-7-research0034.
Kutilin DS, Mogushkova KA. Effect of anthracycline antitumor antibiotics upon transcription activity of cancer-testis antigens in model experiments with HeLa cells. Medical Immunology (Russia) 2019; 21(3): 539–546. [online]. https://doi.org/10.15789/1563-0625-2019-3-539-546.
Balcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. BMC Biotechnol 2011; 11(1): 70. doi: 10.1186/1472-6750-11-70.
Krishnan A, Zhang R, Yao V et al. Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder. Nature Neuroscience 2016; 19(11):1454–1462. doi: 10.1038/nn.4353.
Genome-scale integrated analysis. [online]. Available from: http://giant.princeton.edu/.
Greene CS, Krishnan A, Wong AK et al. Understanding multicellular function and disease with human tissue-specific networks. Nature Genet 2015; 47(6): 569–576. doi: 10.1038/ng.3259w.
Ding J, Li X, Hu H. TarPmiR: a new approach for microRNA target site prediction. Bioinformatics 2016; 32(18): 2768–2775. doi:10.1093/bioinformatics/btw318.
Backes C, Khaleeq QT, Meese E et al. miEAA: microRNA enrichment analysis and annotation. Nucleic Acids Res 2016; 44(W1):W110–W116. doi: 10.1093/nar/gkw345.
Warde-Farley D, Donaldson SL, Comes O et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010; 38(2): W214–W220. doi: 10.1093/nar/gkq537.
Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010; 11(5): R53. doi: 10.1186/gb-2010-11-5-r53.
Sandler HM, Mirhadi AJ. Radical radiotherapy for prostate cancer is the only way to go. Oncology (Williston Park) 2009; 23(10): 840–843.
Geldof AA, Plaizier M, Duivenvoorden I et al. Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J. Cancer Res Clin Oncol 2003; 129(3): 175–182. doi: 10.1007/s00432-002-0412-8.
Lomax M, Folkes L, O’Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol 2013; 25(10): 578–585. doi: 10.1016/j.clon.2013.06.007.
Yao M, Rogers L, Suchowerska N et al. Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target. Radiother Oncol 2018;128(2): 283–300. doi: 10.1016/j.radonc.2018.05.021.
Mailand N, Bekker-Jensen S, Faustrup H et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007; 131(5): 887–900. doi: 10.1016/j.cell.2007.09.040.
Scully R, Xie A. Double strand break repair functions of histone H2AX. Mutat Res 2013; 750(1–2): 5–14. doi:10.1016/j.mrfmmm.2013.07.007.
Bekker-Jensen S, Lukas C, Kitagawa R et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol 2006; 173(2): 195–206. doi: 10.1083/jcb.200510130.
Wang CX, Jimenez-Sainz J, Jensen RB et al. The post-synaptic function of Brca2. Scientific Reports 2019; 9(1): 4554. doi:10.1038/s41598-019-41054-y.
Holloman WK. Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol 2011; 18(7): 748–754. doi: 10.1038/nsmb.2096.
Mijic S, Zellweger R, Chappidi N et al. Replication fork reversal triggers fork degradation in BRCA2-defective cells. Nat Commun 2017; 8(1): 859. doi: 10.1038/s41467-017-01164-5.
Sartori AA, Lukas C, Coates J et al. Human CtIP promotes DNA end resection. Nature 2007; 450(7169): 509–514. doi: 10.1038/nature06337.
Watson J. Molecular biology of the gene. New York: Cold Spring Harbor Laboratory Press 2008: 265–278.
Ntranos A, Casaccia P. Bromodomains: translating the words of lysine acetylation into myelin injury and repair. Neurosci Lett 2016; 625: 4–10. doi: 10.1016/j.neulet.2015.10.015.
Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395–419. doi: 10.1146/annurev.immunol.16.1.395.
Morgan DL. The cell cycle: principles of control. London: New Science Press 2007: 30–31.
Mitrea DM, Yoon MK, Ou L et al. Disorder-function relationships for the cell cycle regulatory proteins p21 and p27. Biol Chem 2012; 393(4): 259–274. doi: 10.1515/hsz-2011-0254.
Inaba T, Matsushime H, Valentine M et al. Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics 1992; 13(3): 565–574. doi: 10.1016/0888-7543(92)90 126-d.
McCubrey JA, Steelman LS, Chappell WH et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012; 3(9): 954–987. doi: 10.18632/oncotarget.652.
Dimitriadi TA, Burtsev DV, Dzhenkova EA et al. Differential expression of microRNAs and their target genes in cervical intraepithelial neoplasias of varying severity. Advances in Molecular Oncology 2020; 7(2): 30–44. doi: 10.17650/2313-805X-2020-7-2-47-61.
Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet 2014; 5: 54. doi: 10.3389/fgene.2014.00054.
Dimitriadi TA, Burtsev DV, Dzhenkova EA et al. Micro-RNA as markers of pre-cancer diseases progression in cervical cancer. [online]. Available from: http://science-education.ru/ru/article/view?id=29529. doi 10.17513/spno.29529